-
2024-519219-32-00
5
2025-06-23
Heart Failure With Reduced Ejection Fraction
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2023-510026-32-00
5
2025-06-11
Generalized Myasthenia Gravis
-
2024-511534-12-00
7
2025-06-10
Advanced or Metastatic Solid Tumours
-
2022-502184-38-00
4
2025-06-06
Rapidly progressive glomerulonephritis
-
2024-513597-22-00
6
2025-04-29
Migraine
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-512901-22-00
5
2025-02-10
Acute Heart Failure
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2024-511497-79-00
4
2024-12-30
Hormone receptor positive (HR+), human epidermal growth factor recepto
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-511465-11-00
5
2024-11-20
Spontaneous lobar ICH
-
2023-504620-26-00
4
2024-11-04
Triple negative breast cancer
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2023-508435-31-00
1
2024-08-09
Advanced Solid Tumors, Advanced Breast Cancer
-
2023-510213-25-01
6
2024-07-08
Takotsubo Syndrome (TT) is an acute cardiac condition
-
2023-505860-12-00
5
2024-06-26
Chronic postsurgical pain after inguinal hernia repair
-
2023-508158-24-00
4
2024-06-25
Moderately to Severely Active Crohn’s Disease
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in